Table 6.
Results from ACR analysis: Mean estimate with 80% credible intervals for each pair-wise comparison
| Comparison | ACR 20 | ACR 50 | ACR 70 | ACRcont |
|---|---|---|---|---|
| Ada vs P |
4.2 (3.4,5.3)* |
5.6 (4.3,7.2)* |
7.0 (4.3,10.9)* |
0.27 (0.25,0.29)* |
| Inf vs P |
3.5 (2.8,4.4)* |
3.4 (2.7,4.4)* |
3.7 (2.3,5.5)* |
0.24 (0.22,0.27)* |
| Eta vs P |
8.8 (5.5,13.9)* |
12.1 (5.7,23.2)* |
30.9 (4.2,123.8)* |
0.32 (0.28,0.35)* |
| Gol vs P |
3.3 (2.3,4.8)* |
4.2 (2.7,6.5)* |
6.5 (2.8,13.3)* |
0.25 (0.21,0.28)* |
| Cert vs P |
10.6 (8.0,14.1)* |
9.5 (6.7,13.5)* |
14.3 (6.8,27.0)* |
0.32 (0.30,0.35)* |
| Inf vs Ada |
0.8 (0.6,1.1) |
0.6 (0.4,0.9)* |
0.5 (0.3,1.0)* |
-0.03 (-0.06,0.00)* |
| Eta vs Ada |
2.1 (1.2,3.4)* |
2.2 (0.96,4.2) |
4.4 (0.6,19.0) |
0.05 (0.01,0.09)* |
| Eta vs Inf |
2.5 (1.5,4.1)* |
3.5 (1.5,6.9)* |
8.3 (1.1,37.7)* |
0.08 (0.03,0.12)* |
| Gol vs Ada |
0.8 (0.5,1.2) |
0.8 (0.4,1.2) |
0.9 (0.4,2.2) |
-0.02 (-0.06,0.02) |
| Gol vs Inf |
0.9 (0.6,1.5) |
1.2 (0.7,2.0) |
1.7 (0.7,4.1) |
0.01 (-0.04,0.05) |
| Gol vs Eta |
0.4 (0.2,0.7)* |
0.3 (0.2,0.8)* |
0.2 (0.0,1.8) |
-0.07 (-0.12,-0.02)* |
| Cert vs Ada |
2.5 (1.8,3.6)* |
1.7 (1.1,2.6)* |
2.1 (0.9,4.7) |
0.05 (0.02,0.09)* |
| Cert vs Inf |
3.0 (2.1,4.3)* |
2.8 (1.8,4.3)* |
3.8 (1.7,8.3)* |
0.08 (0.05,0.12)* |
| Cert vs Eta |
1.2 (0.7,2.0) |
0.8 (0.4,1.8) |
0.5 (0.1,3.6) |
0.01 (-0.04,0.05) |
| Cert vs Gol |
3.2 (2.0,5.1)* |
2.3 (1.3,3.9)* |
2.2 (0.8,6.4) |
0.08 (0.03,0.12)* |
| σ | 0.2 (0.0,0.4) | 0.2 (0.0,0.4) | 0.5 (0.0,0.8) | 0.03 (0.01,0.04) |
Significant results are marked with ∗. Outcome measures are ORs for ACR 20, ACR 50 and ACR 70 and % improvement for ACRcont. Ada=adalimumab; Inf=infliximab; Eta=etanercept; Gol=golimumab, Cert=certolizumab, P=placebo, σ=between trial SD.